SAB Biotherapeutics, Inc. (SABS)Healthcare | Biotechnology | Miami Beach, United States | NasdaqCM
3.83 USD
-0.03
(-0.908%) ⇩
(April 21, 2026, 3:49 p.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:53 p.m. EDT
SABS Bio is unlocking capital efficiently ($85M offering) to fuel SAB-142 trials, creating a clear 'value accumulation' thesis that disconnects current price (~$3.85) from the ~$9.50 analyst mean. While short-term volatility remains muted due to OI skew on puts, the institutional footing suggests a medium-term turnaround is priced on the upside, making the current levels a calculated entry despite negative earnings. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.041034 |
| AutoETS | 0.049855 |
| AutoARIMA | 0.049855 |
| MSTL | 0.050770 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 70% |
| H-stat | 0.10 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.029 |
| Excess Kurtosis | 0.72 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.928 |
| Market Cap | 268,804,608 |
| Forward P/E | -11.59 |
| Beta | 0.61 |
| Website | https://www.sab.bio |
As of April 18, 2026, 11:53 p.m. EDT: Speculators are exhibiting a strong bullish streaker bias in the medium-to-long term. In the July 17 expiration, OTM 4.50-5.00 calls show significantly higher OI concentration (+200% gain) compared to puts, indicating a bet on upside momentum without immediate earnings fear. Conversely, the near-term (April 17) market is neutral-to-slightly bearish, with OTM puts (2.50-3.00) holding the majority of Open Interest, suggesting protection at current levels or a catch-down play. Volatility is compressed in short-dated contracts, reflecting low near-term fear despite the large equity raise.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.9692307 |
| Address1 | 777 W 41st St. |
| All Time High | 129.0 |
| All Time Low | 1.0 |
| Ask | 4.76 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 350,180 |
| Average Daily Volume3 Month | 555,718 |
| Average Volume | 555,718 |
| Average Volume10Days | 350,180 |
| Beta | 0.613 |
| Bid | 2.78 |
| Bid Size | 2 |
| Book Value | 3.182 |
| City | Miami Beach |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.825 |
| Current Ratio | 9.461 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 3.87 |
| Day Low | 3.68 |
| Debt To Equity | 3.928 |
| Display Name | SAB Biotherapeutics |
| Earnings Timestamp End | 1,754,942,400 |
| Earnings Timestamp Start | 1,754,510,400 |
| Ebitda | -45,871,776 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.311 |
| Enterprise Value | 106,029,288 |
| Eps Current Year | -0.3 |
| Eps Forward | -0.33 |
| Eps Trailing Twelve Months | -0.79 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.9258 |
| Fifty Day Average Change | -0.10080004 |
| Fifty Day Average Change Percent | -0.025676304 |
| Fifty Two Week Change Percent | 196.92307 |
| Fifty Two Week High | 6.6 |
| Fifty Two Week High Change | -2.7749999 |
| Fifty Two Week High Change Percent | -0.42045453 |
| Fifty Two Week Low | 1.3 |
| Fifty Two Week Low Change | 2.525 |
| Fifty Two Week Low Change Percent | 1.9423078 |
| Fifty Two Week Range | 1.3 - 6.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,612,881,000,000 |
| Float Shares | 34,878,532 |
| Forward Eps | -0.33 |
| Forward P E | -11.590909 |
| Free Cashflow | -21,992,690 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 86 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -33,352,332 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00962 |
| Held Percent Institutions | 0.5873 |
| Implied Shares Outstanding | 70,275,715 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,704,412,800 |
| Last Split Factor | 1:10 |
| Long Business Summary | SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida. |
| Long Name | SAB Biotherapeutics, Inc. |
| Market | us_market |
| Market Cap | 268,804,608 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_268941400 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 4,261,282 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 271,264,256 |
| Number Of Analyst Opinions | 8 |
| Open | 3.87 |
| Operating Cashflow | -44,775,112 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 305 845 2813 |
| Previous Close | 3.86 |
| Price Eps Current Year | -12.75 |
| Price Hint | 4 |
| Price To Book | 1.2020742 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.132 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.034999847 |
| Regular Market Change Percent | -0.9079079 |
| Regular Market Day High | 3.87 |
| Regular Market Day Low | 3.68 |
| Regular Market Day Range | 3.68 - 3.87 |
| Regular Market Open | 3.87 |
| Regular Market Previous Close | 3.86 |
| Regular Market Price | 3.825 |
| Regular Market Time | 1,776,800,963 |
| Regular Market Volume | 383,943 |
| Return On Assets | -0.28198 |
| Return On Equity | 0.14959 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 70,275,714 |
| Shares Percent Shares Out | 0.0356 |
| Shares Short | 2,504,815 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,613,558 |
| Short Name | SAB Biotherapeutics, Inc. |
| Short Percent Of Float | 0.037100002 |
| Short Ratio | 2.82 |
| Source Interval | 15 |
| State | FL |
| Symbol | SABS |
| Target High Price | 15.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 9.5 |
| Target Median Price | 7.0 |
| Total Cash | 96,592,456 |
| Total Cash Per Share | 1.896 |
| Total Debt | 5,950,681 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.79 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.22531 |
| Two Hundred Day Average Change | 0.59968996 |
| Two Hundred Day Average Change Percent | 0.1859325 |
| Type Disp | Equity |
| Volume | 383,943 |
| Website | https://www.sab.bio |
| Zip | 33,140 |